Literature DB >> 26864862

XELOX vs. FOLFOX in metastatic colorectal cancer: An updated meta-analysis.

Yu Guo1, Bing-Hong Xiong2, Tao Zhang3, Yong Cheng1, Li Ma4.   

Abstract

This meta-analysis aims to evaluate chemotherapy with XELOX (capecitabine plus oxaliplatin) versus FOLFOX (fluorouracil plus oxaliplatin) as a treatment for metastatic colorectal cancer (mCRC) in terms of efficacy and safety. Only randomized controlled trials (RCTs) comparing XELOX versus FOLFOX were included. A total of 4,363 patients from eight RCTs were available for analysis. Pooled analysis revealed that there were no statistical differences between both arms in OS, and ORR. XELOX arm had a higher incidence of thrombocytopenia, hand-foot syndrome, and diarrhea, whereas neutropenia had a higher incidence in the FOLFOX group. For mCRC, the effect of XELOX is similar to FOLFOX.

Entities:  

Keywords:  Capecitabine; Colorectal cancer; Fluorouracil; Oxaliplatin

Mesh：

Substances：

Year:  2016        PMID： 26864862     DOI： 10.3109/07357907.2015.1104689

Source DB:  PubMed          Journal:  Cancer Invest        ISSN： 0735-7907            Impact factor:   2.176


  23 in total

1.  Preoperative FOLFOX in resectable locally advanced rectal cancer can be a safe and promising strategy: the R-NAC-01 study.

Authors:  Nobuki Ichikawa; Shigenori Homma; Tohru Funakoshi; Masahiro Hattori; Masanori Sato; You Kamiizumi; Kazuyoshi Omori; Masaru Nomura; Ryoichi Yokota; Masahiko Koike; Hirofumi Kon; Keisa Takeda; Hiroyuki Ishizu; Kunihiro Hirose; Daisuke Kuraya; Takahisa Ishikawa; Ryohei Murata; Hiroaki Iijima; Futoshi Kawamata; Tadashi Yoshida; Yosuke Ohno; Nozomi Minagawa; Norihiko Takahashi; Akinobu Taketomi
Journal:  Surg Today       Date:  2019-03-05       Impact factor: 2.549

2.  Cancer Treatment Adaptations in the COVID-19 Era.

Authors:  Federico Waisberg; Diego Enrico; Martín Angel; Matías Chacón
Journal:  JCO Oncol Pract       Date:  2020-04-23

Review 3.  An Update on Randomized Clinical Trials in Metastatic Colorectal Carcinoma.

Authors:  Naruhiko Ikoma; Kanwal Raghav; George Chang
Journal:  Surg Oncol Clin N Am       Date:  2017-08-04       Impact factor: 3.495

Review 4.  Optimal First-Line Therapy for Metastatic Adenocarcinoma of the Esophagus.

Authors:  Midhun Malla; Jacob Fuqua; Sarbajit Mukherjee; Richard M Goldberg
Journal:  Curr Treat Options Oncol       Date:  2022-10-22

5.  Cytokine-induced killer cells/dendritic cells-cytokine induced killer cells immunotherapy combined with chemotherapy for treatment of colorectal cancer in China: a meta-analysis of 29 trials involving 2,610 patients.

Authors:  Lei Zhang; Ying Mu; Anqi Zhang; Jiaping Xie; Shuangfeng Chen; Fang Xu; Weihua Wang; Yingxin Zhang; Shaoda Ren; Changhui Zhou
Journal:  Oncotarget       Date:  2017-07-11

Review 6.  New Trends in the Therapeutic Approach to Metastatic Colorectal Cancer.

Authors:  Julia Sánchez-Gundín; Ana María Fernández-Carballido; Lidia Martínez-Valdivieso; Dolores Barreda-Hernández; Ana Isabel Torres-Suárez
Journal:  Int J Med Sci       Date:  2018-04-03       Impact factor: 3.738

7.  Cost-utility analysis of 5-fluorouracil and capecitabine for adjuvant treatment in locally advanced rectal cancer.

Authors:  Kanyarat Katanyoo; Imjai Chitapanarux; Tharatorn Tungkasamit; Somvilai Chakrabandhu; Marisa Chongthanakorn; Rungarun Jiratrachu; Apiradee Kridakara; Kanokpis Townamchai; Pooriwat Muangwong; Chokaew Tovanabutra; Kittisak Chomprasert
Journal:  J Gastrointest Oncol       Date:  2018-06

Review 8.  Advances and new frontiers for immunotherapy in colorectal cancer: Setting the stage for neoadjuvant success?

Authors:  Nuttavut Sumransub; Kornpong Vantanasiri; Ajay Prakash; Emil Lou
Journal:  Mol Ther Oncolytics       Date:  2021-05-14       Impact factor: 7.200

9.  FOLFOX regimen plus dendritic cells-cytokine-induced killer cells immunotherapy for the treatment of colorectal cancer: a meta-analysis.

Authors:  Yan Liu; Zhong Zheng; Qixin Zhang; Xinling Zhou; Yikuan Feng; Anquan Yan
Journal:  Onco Targets Ther       Date:  2017-05-18       Impact factor: 4.147

10.  A Network Pharmacology Approach to Uncover the Multiple Mechanisms of Hedyotis diffusa Willd. on Colorectal Cancer.

Authors:  Xinkui Liu; Jiarui Wu; Dan Zhang; Kaihuan Wang; Xiaojiao Duan; Xiaomeng Zhang
Journal:  Evid Based Complement Alternat Med       Date:  2018-02-12       Impact factor: 2.629
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.